Results 231 to 240 of about 68,403 (337)

Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract AZD7442, a combination of extended half‐life monoclonal antibodies tixagevimab and cilgavimab, was shown to neutralize previously circulating SARS‐CoV‐2 variants. This study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD7442 in healthy Chinese adults. In this randomized, placebo‐controlled, Phase 1 study, AZD7442
Nanyang Li   +11 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan   +6 more
wiley   +1 more source

Daily Cortisol Production Rate in Man Determined by Stable Isotope Dilution/Mass Spectrometry

open access: bronze, 1991
Nora V. Esteban   +6 more
openalex   +1 more source

Proton‐Coupled Electron Transfer Deoxygenation of Pyridine N‐Oxide: A Mechanistic Study

open access: yesChemPhysChem, EarlyView.
This study explores the electrochemical reductive deoxygenation of pyridine N‐oxide, highlighting proton‐coupled electron transfers. A first stepwise electron–proton transfer leads to the protonated pyridine N‐oxide radical. Kinetic data support a concerted dissociative electron transfer mechanism over homolytic cleavage for NO bond in the subsequent ...
Céline Naddour   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy